{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:50:12Z","timestamp":1786737012538,"version":"build-2736575974"},"reference-count":48,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) is now established as the gold-standard imaging modality for both staging and response assessment in follicular lymphoma (FL). In this Perspective, we propose where PET can, and cannot, guide clinicians in their therapeutic approach. PET at diagnosis and pretreatment is important for staging, with greater sensitivity compared with standard CT, and consequent improved outcomes in truly limited-stage FL. Small data sets suggesting that a high baseline standardized uptake value (SUVmax) identifies de novo histologic transformation (HT) have not been corroborated by data from GALLIUM, the largest prospective study to examine modern therapies for FL. Nonetheless, the role of baseline quantitative PET measures requires further clarification. The median survival of patients with newly diagnosed FL is now potentially &amp;gt;20 years. Treatment of symptomatic FL aims to achieve remission and optimize quality of life for as long as possible, with many patients achieving a \u201cfunctional cure\u201d at the cost of unwanted treatment effects. Several studies have identified end-of-induction (EOI) PET after initial chemoimmunotherapy in patients with a high tumor burden as strongly predictive of both progression-free and overall survival, and EOI PET is being evaluated as a platform for response-adapted treatment. Unmet needs remain: improving the inferior survival for patients remaining PET positive and quantifying the progression-free survival and time to next treatment advantage, and additional toxicity of anti-CD20 maintenance in patients who achieve complete metabolic remission. In the absence of an overall survival advantage for frontline antibody maintenance, the question of using PET to guide the therapeutic approach is more important than ever in the context of the COVID-19 pandemic.<\/jats:p>","DOI":"10.1182\/blood.2020008243","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T20:54:13Z","timestamp":1626296053000},"page":"1631-1641","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Is it time for PET-guided therapy in follicular lymphoma?"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"first","affiliation":[{"name":"Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Pettitt","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2022031715492546800_B1","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022031715492546800_B2","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol."},{"issue":"35","key":"2022031715492546800_B3","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022031715492546800_B4","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol."},{"issue":"27","key":"2022031715492546800_B5","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"27","key":"2022031715492546800_B6","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group [published correction appears in J Clin Oncol. 2016;34(21):2562]","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022031715492546800_B7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol."},{"issue":"12","key":"2022031715492546800_B8","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2022031715492546800_B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"2022031715492546800_B10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","article-title":"Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma","volume":"19","author":"Elstrom","year":"2008","journal-title":"Ann Oncol."},{"issue":"1","key":"2022031715492546800_B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdj024","article-title":"Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET\/CT era?","volume":"17","author":"Raanani","year":"2006","journal-title":"Ann Oncol."},{"issue":"10","key":"2022031715492546800_B12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2967\/jnumed.116.181347","article-title":"18F-FDG PET\/CT in lymphoma: has imaging-directed personalized medicine become a reality?","volume":"58","author":"Barrington","year":"2017","journal-title":"J Nucl Med."},{"issue":"7","key":"2022031715492546800_B13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428194.2016.1253836","article-title":"Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients","volume":"58","author":"Rai","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022031715492546800_B14","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3109\/10428194.2013.770151","article-title":"Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database","volume":"54","author":"Abou-Nassar","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"2022031715492546800_B15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","author":"Batlevi","year":"2020","journal-title":"Eur J Cancer."},{"issue":"3","key":"2022031715492546800_B16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG [published correction appears in Blood. 2019;134(3):331]","volume":"133","author":"Brady","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022031715492546800_B17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022031715492546800_B18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","article-title":"Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma","volume":"55","author":"Cerci","year":"2014","journal-title":"J Nucl Med."},{"issue":"1","key":"2022031715492546800_B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood."},{"issue":"6","key":"2022031715492546800_B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdw137","article-title":"The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET\/CT: a Danish-Canadian study","volume":"27","author":"Alzahrani","year":"2016","journal-title":"Ann Oncol."},{"issue":"8","key":"2022031715492546800_B21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/bloodadvances.2019001261","article-title":"Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA","volume":"4","author":"Rutherford","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"2022031715492546800_B22","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/bloodadvances.2020001579","article-title":"Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information [published correction appears in Blood Adv. 2020;4(15):3558]","volume":"4","author":"Nakajima","year":"2020","journal-title":"Blood Adv."},{"issue":"21","key":"2022031715492546800_B23","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022031715492546800_B24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol."},{"issue":"7","key":"2022031715492546800_B25","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica."},{"issue":"9759","key":"2022031715492546800_B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"issue":"7","key":"2022031715492546800_B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J\u00a0Clin Oncol."},{"issue":"22","key":"2022031715492546800_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1101.1101","article-title":"Low SUVmax measured on baseline FDG-PET\/CT and elevated beta2 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies","volume":"128","author":"Cottereau","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2022031715492546800_B29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","article-title":"Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets","volume":"1","author":"Bolen","year":"2017","journal-title":"Blood Adv."},{"issue":"12","key":"2022031715492546800_B30","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/bloodadvances.2020004051","article-title":"Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma","volume":"5","author":"Nath","year":"2021","journal-title":"Blood Adv."},{"issue":"15","key":"2022031715492546800_B31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood."},{"issue":"14","key":"2022031715492546800_B32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"issue":"30","key":"2022031715492546800_B33","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-Burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol."},{"key":"2022031715492546800_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line immunochemotherapy and antibody maintenance in the phase III GALLIUM study [abstract]","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood."},{"key":"2022031715492546800_B35","article-title":"A fully automated measurement of total metabolic tumor burden in diffuse large B-cell lymphoma and follicular lymphoma [abstract]","volume":"134","author":"J","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2022031715492546800_B36","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med."},{"key":"2022031715492546800_B37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"2022031715492546800_B38","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","article-title":"Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background","volume":"51","author":"Itti","year":"2010","journal-title":"J Nucl Med."},{"issue":"1","key":"2022031715492546800_B39","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","article-title":"The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma","volume":"8","author":"Barrington","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022031715492546800_B40","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol."},{"issue":"3","key":"2022031715492546800_B41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","article-title":"PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study","volume":"41","author":"Tychyj-Pinel","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022031715492546800_B42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8025","article-title":"First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: prognostic value of PET-CT status after long-term follow-up [abstract]","volume":"38","author":"Nielsen","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022031715492546800_B43","author":"Mir"},{"key":"2022031715492546800_B44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hon.110_2629","article-title":"Response oriented maintenance therapy in advanced follicular lymphoma. Results of the interim analysis of the Foll12 trial conducted by the Fondazione Italiana Linfomi","volume":"37","author":"Federico","year":"2019","journal-title":"Hematol Oncol."},{"key":"2022031715492546800_B45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.35_2629","article-title":"Ncri Petrea trial: a phase 3 evaluation of pet-guided, response adapted therapy in patients with previously untreated, advanced-stage, high-tumour-burden follicular lymphoma","volume":"37","author":"Pettitt","year":"2019","journal-title":"Hematol Oncol."},{"issue":"10","key":"2022031715492546800_B46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"issue":"31","key":"2022031715492546800_B47","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol."},{"key":"2022031715492546800_B48","first-page":"171","article-title":"Metabolic (PET) and MRD response confer reduced risk of progression or death in patients treated within the phase III GALLIUM study [abstract]","volume":"2","author":"Pott","year":"2018","journal-title":"HemaSphere."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/11\/1631\/1882011\/bloodbld2020008243c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/11\/1631\/1882011\/bloodbld2020008243c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:12:08Z","timestamp":1647540728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/11\/1631\/476386\/Is-it-time-for-PET-guided-therapy-in-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,3,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008243","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}